JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Pharvaris to $20 from $23 and keeps an Outperform rating on the shares. Management continues to execute on all fronts with key inflection points over the next 9-12 months, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PHVS:
- Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Pharvaris announces Phase 2 data from RAPIDe-1 Study of PHVS416
- Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
- Pharvaris to Present in Upcoming March Investor Conferences
- Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
